8-K: Enfusion Announces Q4 and Full Year 2024 Results; Acquisition by Clearwater Analytics Expected to Close in Q2 2025

Enfusion reports a 13.9% increase in Q4 revenue and announces its acquisition by Clearwater Analytics, expected to close in the second quarter of 2025.

Summary

• Enfusion, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenue for Q4 2024 was $52.9 million, a 13.9% increase compared to the same period in the prior year.
• Gross Profit for Q4 was $36.5 million, with a Gross Profit Margin of 69.0%.
• Net Income for Q4 was $0.2 million, resulting in a Net Income Margin of 0.3%.
• Adjusted EBITDA for Q4 was $12.3 million, a 25.3% increase year-over-year.
• Annual Recurring Revenue (ARR) reached $210.4 million at the end of December 2024, up 13.6% from December 2023.
• The Net Dollar Retention Rate (NDR) was 103.0%, compared to 102.1% in December 2023.
• Enfusion added 41 new clients in Q4, bringing the total client count to 916 as of December 31, 2024.
• For the full year 2024, total revenue was $201.6 million, a 15.5% increase from $174.5 million in the prior year.
• The Gross Profit Margin for the full year was 67.8%, compared to 67.0% in the prior year.
• The Adjusted EBITDA Margin for the full year was 21.2%, compared to 18.1% in the prior year.
• On January 13, 2025, Enfusion announced its acquisition by Clearwater Analytics, expected to close in the second quarter of 2025, pending shareholder and regulatory approvals.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth and the pending acquisition, but tempered by the lack of future guidance and a decrease in Net Income Margin.

Positives

• Enfusion experienced revenue growth in both Q4 and full year 2024.
• Adjusted EBITDA and Adjusted EBITDA Margin improved year-over-year.
• ARR and NDR metrics indicate strong client retention and revenue expansion.
• The acquisition by Clearwater Analytics could provide further opportunities for growth and synergy.

Negatives

• Net Income Margin decreased for the full year 2024, from 5.3% to 1.9%.
• The company will not be hosting an earnings call or providing financial guidance for 2025 due to the pending acquisition.

Risks

• The acquisition by Clearwater Analytics is subject to shareholder and regulatory approvals, and customary closing conditions.
• Potential delays or failure to close the acquisition could impact Enfusion's business.
• The company faces risks related to business disruptions, retention of key personnel, and adverse reactions from business relationships during the pendency of the acquisition.

Future Outlook

Due to the pending acquisition by Clearwater Analytics, Enfusion will not be hosting an earnings conference call, releasing a Shareholder Letter, or providing financial guidance for fiscal 2025.

Industry Context

Enfusion's acquisition by Clearwater Analytics reflects a trend of consolidation in the financial technology sector, as companies seek to expand their product offerings and customer base. This move positions Clearwater Analytics to offer a more comprehensive suite of solutions for investment managers.

Comparison to Industry Standards

• Enfusion's ARR growth of 13.6% is comparable to other SaaS companies in the financial services industry, such as Blackbaud which reported 10.8% organic recurring revenue growth in their latest annual report.
• The Net Dollar Retention Rate of 103% indicates healthy customer retention and expansion, aligning with industry benchmarks for successful SaaS businesses.
• Companies like SS&C Technologies and FactSet also operate in the investment management software space, and their financial performance can be used as a benchmark to evaluate Enfusion's results.

Stakeholder Impact

• Shareholders will have the opportunity to vote on the proposed acquisition.
• Employees face potential changes related to the integration with Clearwater Analytics.
• Customers may experience changes in product offerings and support as a result of the acquisition.

Next Steps

• Enfusion shareholders will vote on the proposed acquisition by Clearwater Analytics.
• Regulatory approvals for the acquisition will be sought.
• The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions.

Key Dates